AQST news

Cleared for final review, Aquestive Therapeutics received a March 16, 2027, FDA decision date for Anaphylm. The drug aims to be the first oral rescue medication for severe allergic reactions, with market relevance focused on the biopharmaceutical antiallergy sector and commercial launch readiness.

Eton Pharmaceuticals and Aquestive Therapeutics announced a U.S. licensing agreement for LIBERVANT buccal film, targeting a U.S. market opportunity exceeding $450 million. The deal is expected to advance Eton's rare disease portfolio and provide a near-term growth opportunity in neurology.

Eton entered an exclusive licensing agreement with Aquestive for LIBERVANT buccal film, targeting a U.S. seizure rescue market exceeding $450 million annually with an anticipated April 2027 commercial launch.

Aquestive Therapeutics named Richard Daly to its board of directors to help prepare for the potential commercial launch of its drug candidate, Anaphylm.

The company filed a resubmission of its NDA for Anaphylm, seeking to address FDA feedback, and updated investors on its AdrenaVerse pipeline during its corporate presentation.

Aquestive Therapeutics announced positive human factors and pharmacokinetic study results for its Anaphylm (dibutepinephrine) sublingual film, supporting its planned NDA resubmission in Q3 2026.